Toft Group Completes Chief Medical Officer Search for aTyr Pharma, Inc. (Nasdaq: LIFE) in San Diego, CA

aTyr Pharma

Executive search firm Toft Group has placed Sanjay Shukla, M.D., M.S. as Chief Medical Officer at aTyr Pharma, Inc. (Nasdaq: LIFE) in San Diego, CA. Dr. Shukla will lead aTyr's clinical efforts to advance Physiocrine-based therapeutics that promote tissue homeostasis for patients with various severe and rare diseases.

Robin Toft, President and CEO of Toft Group said: “We are thrilled to have represented Dr. Shukla and connected him with his new role as aTyr’s Chief Medical Officer. We expect that he will make an exceptional contribution to the company’s continued growth and success.”

In Dr. Shukla's most recent role as Vice President and Global Head of Integrated Medical Services for Novartis, he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. These included brands such as Gilenya™, Cosentyx™, and Entresto™. In addition, Dr. Shukla led the creation and development of the Real World Evidence Center for Excellence as well as incubating the Digital Strategy group within Global Medical Affairs. Previously, he was Chief Executive Officer of RxMd, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates. Prior to that Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma and Aspreva Pharmaceuticals. Dr. Shukla received his M.D. from Howard University, and his M.S. in Epidemiology and Biostatistics from the University of Maryland.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies - from venture backed start-ups to Fortune 500 corporations.